Compensating for intrinsic limitations: While there is no exhaustive catalog of principles for this selection, several core strategies stand out. The most familiar is combining agents with entirely distinct mechanisms of action—such as pairing a platinum agent with paclitaxel—to strike the disease through independent pathways. However, a more sophisticated approach is designing combinations where one agent actively compensates for another's structural limitation. Many advanced immunotherapies excel at expanding the population of cytotoxic immune cells, yet they share a single, fatal bottleneck: those cells cannot physically penetrate "cold" solid tumors. An agent that converts a cold tumor into a hot one—as we believe Elenagen does by remodeling the tumor's microenvironmental architecture—can unlock the locked-out activity of companion therapies that would otherwise stall at the tumor's edge.

Disabling treatment-induced resistance loops: A closely related principle is disabling the tumor's capacity to neutralize treatment in real time. Gemcitabine, for example, activates NF-B, and NF-B in turn drives cellular resistance to gemcitabine. Because Elenagen suppresses NF-B activation, combining the two is highly rational, breaking a vicious feedback loop and pointing toward a broader class of synergistic combinations with agents whose efficacy is otherwise blunted by inflammatory signaling.

Looking further ahead, I expect scheduling to matter immensely: chronotherapy, in which therapeutic administration is tightly coordinated with the body's circadian rhythms, represents a highly promising, underutilized dimension of trial design. Finally, we must pair these regimens more thoughtfully with evidence-based supportive care and nutrition to ease the cumulative toxicity patients bear.

The direction of travel is unmistakable: the industry is moving decisively away from the romanticized search for a single, silver-bullet drug, and toward intelligent, collaborative, biologically reasoned combinations.

What opportunities do emerging biotech ecosystems outside traditional pharmaceutical hubs bring to global innovation?

Over the past four years, the world has once again fractured into competing geopolitical axes, and this trend will likely persist — and may well deepen. Yet there is one arena into which we must never allow these divisions to extend: the development of medicines. Disease is the common adversary of all humanity, and the search for cures must remain a shared endeavor even as other forms of cooperation fray.

Seen in that light, the rise of new innovation centers is doubly welcome. Innovation in our industry is no longer the exclusive province of Boston, San Francisco, and Basel. Emerging ecosystems across Asia-Pacific, Latin America, the Middle East, and Eastern Europe are contributing scientific talent, clinical-trial capacity, manufacturing capability, and capital — and that diffusion is good for global innovation and for patients.

The opportunities are concrete. Rigorous clinical trials can often be conducted in these regions efficiently and with access to diverse, well-characterized patient populations, generating high-quality data that can then be brought to the FDA and EMA. Regional manufacturing, including for newer modalities, is expanding capacity and resilience. And strategic, sometimes non-dilutive, capital from regional companies and conglomerates can fund development in ways that complement traditional venture financing. Much of our own randomized clinical evidence was generated outside the United States, which allowed a small company to produce a meaningful dataset before entering the larger and more expensive Western trial and regulatory process.

For the Asia-Pacific region in particular, the strengths are striking: deep pools of capital, world-class manufacturing, fast-growing oncology markets, and integrated pharmaceutical companies in Japan, Korea, China, and elsewhere that are increasingly eager to co-develop and commercialize innovative assets rather than simply in-license late-stage products. Forums such as the BIO International Convention exist precisely to connect originators of science with the regional partners who can develop, manufacture, and commercialize it. The most effective model I see is one in which science and capital flow across borders — a discovery made anywhere can be advanced through partnerships spanning several regions.

There are caveats worth naming honestly: the need for regulatory harmonization, ensuring data quality and cross-agency acceptance, and attention to intellectual property and geopolitical considerations. But these are manageable, and the upside is substantial. If the geopolitical map is fragmenting, the map of disease is not — illness respects no border, ideology, or alliance. That is precisely why the shared fight against disease can, and should, become a unifying ground on which nations belonging to different axes continue to collaborate. A more distributed innovation landscape means more shots on goal against our common enemies — and faster, more affordable routes to bringing therapies to patients everywhere, whichever side of any line they happen to live on.

Which scientific advances are most likely to define the future of cancer immunotherapy?

One cannot predict the future, least of all in science. However, there are a few fundamental shifts in biological thinking that I believe are rapidly hardening into definitive drug-development strategies.

From silencing single words to reshaping the dialect: The cells of a tissue—and immune cells above all—communicate in a complex, fluid language whose words are interleukins, cytokines, and other signaling molecules. For most of recent history, the industry's approach has been to intercept a single word we judged to be a malicious command: an antibody that blocks one specific cytokine, or VEGF, or another discrete signal. The structural trouble is that biological language, like any natural language, is highly redundant. Silence one word—say, "hit"—and the system soon restores the malicious meaning with a biological synonym: "punch." Bispecific antibodies, which engage two targets at once, are a welcome step, but to my mind they represent only an incremental improvement; they still operate at the level of individual words. The deeper, transformative advance will come from changing the entire dialect—shifting a tissue systemically out of a pathological mode of communication, such as chronic inflammation or intratumoral immunosuppression, and back toward a healthy, homeostatic dialogue.

From attacking the cancer cell to reprogramming its neighbors: The second profound shift is moving away from acting directly on the tumor cell and toward acting on it indirectly, through the cells that surround it. Our own work with Elenagen illustrates this exact principle. The plasmid acts selectively on mesenchymal stromal cells (MSCs), in effect making them behave younger: they cease secreting a pro-inflammatory secretome—itself a chorus of many molecular words that together sustain chronic inflammation—and begin secreting an anti-inflammatory one instead.

What I find most striking is the secondary cascade. Although only a limited number of cells take up the plasmid directly, the altered secretome those cells release travels dynamically through the body, reprogramming distant stromal cells much like the plasmid itself would. The organism thus propagates and amplifies the effect of a small, localized amount of the original drug, carrying its comprehensive therapeutic effect far beyond the cells originally treated. A therapy that successfully recruits the body to spread its own corrective signal is a fundamentally different proposition from a conventional agent that must physically reach every single target cell itself.

Decoding the grammar of cellular networks: These are incredibly complex, highly networked systems, and as an industry, we are only beginning to truly read them. I expect artificial intelligence to become an indispensable partner in this specific effort—not merely predicting structures, but actively helping us decode the intricate grammar of cellular communication. AI will teach us how to efficiently shift a diseased dialect back toward a healthy conversation. If the last era of immunotherapy was defined by aggressively blocking the wrong signals, the next will belong to platforms capable of restoring the right conversation.